

Total synthesis of the putative structure of the proposed Banyasin A

Xuguang Gao¹, Qi Ren¹, Sun Choi², Zhengshuang Xu^{1*} and Tao Ye^{1,3*}

¹ Laboratory of Chemical Genomics, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, China, ² National Leading Research Laboratory of Molecular Modeling and Drug Design, College of Pharmacy, Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul, South Korea, ³ Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hong Kong, China

OPEN ACCESS

Edited by:

Bastien Nay,
Centre National de la Recherche
Scientifique, France

Reviewed by:

Fang-Rong Chang,
Kaohsiung Medical University, Taiwan
Haruhiko Fuwa,
Tohoku University, Japan

*Correspondence:

Zhengshuang Xu,
Laboratory of Chemical Genomics,
School of Chemical Biology and
Biotechnology, Peking University
Shenzhen Graduate School,
Shenzhen, 518055, China
xuzs@pkusz.edu.cn;

Tao Ye,

Department of Applied Biology and
Chemical Technology, The Hong Kong
Polytechnic University, Hong Kong,
China
tao.ye@polyu.edu.hk

Specialty section:

This article was submitted to Chemical
Biology, a section of the journal
Frontiers in Chemistry

Received: 12 January 2015

Paper pending published:

28 January 2015

Accepted: 02 March 2015

Published: 17 March 2015

Citation:

Gao X, Ren Q, Choi S, Xu Z and Ye T
(2015) Total synthesis of the putative
structure of the proposed Banyasin A.
Front. Chem. 3:19.
doi: 10.3389/fchem.2015.00019



The first total synthesis of four possible isomers of a molecule possessing the configuration proposed for Banyasin A is described. The structure synthesized appears to be different from that of the natural product.

Keywords: Banyasin A, total synthesis, stereoselective, cyclopeptide, chitinase inhibitors

Introduction

Secondary metabolites produced by cyanobacteria are key synthetic targets in the quest for new leads in the pharmaceutical industry (Singh et al., 2011). One particular species, *Nostoc* sp., (Rawat and Bhargava, 2011; Niedermeyer, 2014) is responsible for the production of a considerable of bioactive cyclopeptide and cyclodepsipeptides with a variety of significant associated biological activities, including antiproliferative activities (Kang et al., 2012) antitoxin against Microcystins (Jokela et al., 2010), inhibition of chymotrypsin (Ploutno and Carmeli, 2002) antimicrobial activities (Ploutno and Carmeli, 2000), selective cytotoxicity (Trimurtulu et al., 1994). Some of the metabolic signatures of cyanobacterial peptides include a high degree of *N*-methylated amino acids, *D*-amino acids, and β -amino acids. We have been interested in marine secondary metabolites, especially the cyclopeptides and cyclodepsipeptides, and view their syntheses as playing a key role in structural confirmation, structural modification, and subsequent activity control. Previous work in our group led to the assignment/revision of a number of natural products including mandelalide A (Lei et al., 2014), lagunamide A (Dai et al., 2012), nocardiozine B (Wang et al., 2012), burkholdac A (Liu et al., 2012), bisebromoamide (Gao et al., 2010), and yanucamide A (Xu et al., 2003). Thus, we were encouraged to consider the synthesis of other natural products of uncertain configuration.

In 2005, Carmeli and Ploutno reported the isolation of banyasin A (**1**) (Figure 1), from cyanobacterium *Nostoc* sp. (Ploutno and Carmeli, 2005). Structurally, banyasin A possesses a 16-membered macrocyclic peptide backbone which is composed of the unique, non-proteinogenic amino acids residues such as 3-amino-2-methyl-5*E*-octenoic acid and L-*N*₈-(*N*-methylcarboxyamidine)arginine. Both the relative stereochemistry and absolute configuration of 3-amino-2-methyl-5*E*-octenoic acid were unassigned in the isolation paper. The final structural determination had to await the total synthesis of the four possible diastereomeric structures proposed for the natural product. Banyasin A was isolated followed by a serine protease inhibition-guided protocol, however, pure banyasin A was found to be inactive toward trypsin inhibition. Banyasin A is structurally closely related to the known chitinase inhibitors argifin and argadin (Figure 1) (Arai et al., 2000; Omura et al., 2000). All these three natural products contained a highly modified arginine at the guanidine moiety. It is known that the dimethylguanylurea fragment of argifin was found to harbor all significant interactions with the chitinase and binds with unusually high efficiency. (Andersen et al., 2008). L-*N*₈-(*N*-methylcarboxyamidine)arginine moiety played the critical role in binding of argifin to its cognate target (Dixon et al., 2009). The 16-membered



macrolactam ring of banyasin A resemble the macrocyclic core of the known chitinase inhibitor argifin. Both banyasin A and argifin are comprised of L-*N*₈-(*N*-methylcarboxyamido)arginine residue. Modeling studies based on conformational analysis and manual docking yielded a binding model of banyasin A to a fungal chitinase (*AfChiB1*) active site, which has the most similar binding mode of argifin to *AfChiB1* (Rao et al., 2005). As a representative compound, **1b** was displayed in **Figure 2**. The rest binding modes of banyasin's diastereomers (**1a**, **1c**, and **1d**) in *AfChiB1* active site were included in support information. Taken together, these studies implied that banyasin A may serve as a potential lead compound

for the development of antifungals and pesticides. The limited supply of banyasin A from its natural source has prevented its full biological characterization. In order to obtain sufficient material for more extensive biological evaluation as well as to determine the absolute configuration of banyasin A, we undertook research to develop a total synthesis of banyasin A with flexibility to enable future SAR development. Herein, we describe our efforts toward the total synthesis of banyasin A.



The retrosynthetic analysis of banyasin A (**1**) is illustrated in **Figure 3**. The *N*-methyl carbamoyl modification of the Arg residue will be conducted as the final step of the synthesis. There are a number of possible positions to close the macrocyclic portion (**2**) of the molecule (**Figure 2**). We chose to close the cyclopeptide via macrolactamization between the alanine and amoa residues because it allowed versatility in the construction of the cyclization precursor (**3**). Because the absolute configuration of the 3-amino-2-methyl-5*E*-octenoic acid residue was not established, the incorporation of four possible diastereomers of the 3-amino-2-methyl-5*E*-octenoic acid residue to afford linear precursor **3** could be exerted in the late stage. Further disconnection of the linear peptide **3** revealed amoa unit (**4**) and a tetrapeptide equivalent, the latter intermediate being traced to the protected amino acids **5**, **6**, **7**, and **8**. (**Figure 3**).

Materials and Methods

Experimental procedure and compound characterization data are furnished in the Supplementary Material.


Results and Discussion

The synthesis commenced from crotylation of 3-benzoyloxy-propionaldehyde (**9**) with Brown's (*E*)-(+)-crotyldiisopinocampheylborane, prepared from (+)-diisopinocampheyl(methoxy)borane, and yielded the *anti*-homoallylic alcohol **10** as a single diastereomer after silica gel chromatography (**Figure 4**). (Brown and Bhat, 1986) The homoallylic alcohol was then converted to its mesylate derivative, followed by exposure of the resulting mesylate to sodium azide in DMF furnished, with inversion of configuration, the corresponding azido derivative **11** in 59% overall yield from aldehyde **9**. The azide moiety of **11** was reduced by the action of triphenylphosphine to afford



the corresponding primary amine, which was then protected as a Boc carbamate (**12**) in 94% yield over two steps. Oxidative cleavage of the olefin of **12** using OsO_4 - NaIO_4 in the presence of 2,6-lutidine afforded an aldehyde, which was further oxidized to the corresponding carboxylic acid by Pinnick oxidation. A subsequent methylation of the carboxylic group using iodomethane and potassium carbonate gave the methyl ester **13** in 72% yield over the three steps. Subsequent removal of the benzyl ether under hydrogenative conditions followed by Dess-Martin oxidation of the resultant primary alcohol gave rise to aldehyde **14** in 79% yield. The Kocienski-modified Julia olefination of aldehyde **14** with sulfone **15** in THF at -78°C delivered olefin **16** as an inseparable mixture of olefin isomers (4:1) in favor of the desired *E* configuration. (Blakemore et al., 1998). Subsequent saponification of the methyl ester gave 3-amino-2-methyl-5*E*-octenoic acid **4a** in 97% yield. Further incorporation of **4a** in the construction of the macrocycle revealed the undesired



geometrical isomer could not be completely removed in the later stage of the synthesis. Bearing in mind the problems encountered with the formation of an inseparable mixture of olefin isomers, we required an alternative approach which could efficiently deliver 3-amino-2-methyl-5*E*-octenoic acid **4** in fairly high purity. Thus, the homoallylic alcohol **10** was protected as its *tert*-butyldimethylsilyl ether and the terminal alkene underwent a substrate-controlled dihydroxylation in the presence of osmium tetroxide to provide **18** as a diastereomeric mixture (3.7:1) of diols in 88% combined yields (**Figure 5**). This mixture was simply exposed to 2,2-dimethoxypropane under acidic conditions to furnish the corresponding acetonide, which was then subjected to hydrogenolysis of the benzyl ether to give rise to **19** in 86% yield for two steps. Dess-Martin oxidation of **19** provided crude aldehyde, which was treated with the anion derived from sulfone **15** and KHMDS. When the olefination was performed in 1,2-dimethoxyethane (DME) at -68°C , we obtained *E/Z*



mixtures (13/1) of olefins **20** in 83% yield. Removal of the TBS group in **20** using TBAF and the resultant secondary hydroxy group engaged in Mitsunobu reactions using diphenylphosphoryl azide (DPPA) (Lal et al., 1977) as the nucleophile to give rise to azide **21** in 78% yield. Acid-catalyzed deprotection of the acetone functionality of **21**, followed by oxidative cleavage of the resulting diol with sodium periodate, followed by Pinnick oxidation (Bal et al., 1981) afforded the carboxylic acid **22a** in 79% yield over three steps. As the absolute configuration of two stereogenic centers in the subunit **4** was not assigned in the original isolation work, our synthetic strategy grew from the desire to have a versatile approach to make all four possible diastereomers of **4**, along with the defined stereochemistry of the disubstituted olefin component. With a practical route to **22a** in hand, we synthesized the other three possible diastereomers (**22b**, **22c**, and **22d**) through the condensation of aldehyde **9** with Brown's (*E*)-(-)-crotyldiisopinocampheylborane, (*Z*)-(+)-crotyldiisopinocampheylborane and (*Z*)-(-)-crotyldiisopinocampheylborane, respectively. Azido acid **22a** was then subjected to hydrogenation in the presence of the palladium on charcoal and the resulting amine was protected as its *tert*-butoxycarbonyl carbamate **4a**.

With the critical amoa fragment in hand, we then turned our attention to the assembly of the remaining amino acids to a tetrapeptide and further elaboration to the linear precursor **3**. Thus, the 2-(trimethylsilyl)-ethoxycarbonyl (Teoc) protecting

group was installed on the the alpha amino group of *N*- δ -Cbz-L-ornithine to afford the orthogonally protected ornithine **5** in 81% yield, which underwent a HATU-mediated coupling reaction with *N*-methyl-L-phenylalanine methyl ester (**6**) to provide dipeptide **24** in 59% yield (Carpino, 1993). Saponification of the methyl ester of **24** produced the corresponding acid, which was then condensed with aspartate **7** in the presence of HATU and triethylamine to provide tripeptide **25** in 83% yield. Tripeptide **25** was submitted to catalytic hydrogenation to remove the benzyl protecting group, and the guanidine function was introduced by reaction with 1,3-di-Boc-2-(trifluoromethanesulfonyl)guanidine (**26**) (Feichtinger et al., 1998) to give **27** in 91% yield. Tripeptide **27** was further elongated to tetrapeptide **28** in 61% yield by a two step sequence, involving (1) hydrolysis of the methyl ester to its free acid, and (2) HATU-mediated condensation of the acid with L-alanine 9-fluorenylmethyl ester (**8**). This set the stage for the introduction of the 3-amino-2-methyl-5E-octenoic acid **4** to complete the synthesis of linear precursor **3**. In the event, the Teoc protecting group of **28** was removed in one step using TBAF in THF to provide the corresponding free amine. Unfortunately, condensation of this amine with acid **4a** using various coupling agents, including HATU, PyAOP, DCC and EDCI, turned out to be relatively slow and led to the formation of **3a** with significant epimerization at the center adjacent to the newly formed amide carbonyl. In general, formation of 20–35% of undesired






FIGURE 8 | Comparison of ^1H NMR of natural and synthetic banyasin A (1a–d).

epimer could be observed during the coupling reaction depending on the reagent employed. We speculated that the conformation of the tetrapeptide **28** may significantly affect the reactivity of the amine and resulted in a slow condensation reaction. Despite this significant setback to our synthetic plan toward banyasin A, we sought that to install the 3-amino-2-methyl-5*E*-octenoic acid unit (**4** or its masked form **22**) to the peptide at earlier stage might avoid epimerization of the C2-methyl group. Gratifyingly, HATU-mediated coupling reaction of azido acid **22a** with the amine derived from tripeptide **27** afforded **29a** in 93% yield. That no epimerization had occurred during this coupling reaction was confirmed by synthesizing the corresponding epimeric material through the condensation of the same amine with azide acid **22c**. Saponification of the methyl ester of **29a** and subsequent condensation of the resultant acid with *L*-alanine 9-fluorenylmethyl ester (**8**) afforded **30a** in 82% yield. Of the various reduction protocols that were examined for converting azido acid **30a** into the corresponding amine, the Staudinger reduction with PMe_3 in $\text{THF}:\text{H}_2\text{O}$ (7:1) proved the most successful. In the event, the Staudinger reduction of the azide and the cleavage of 9-fluorenylmethyl ester with aqueous NH_4OH were carried out in a one-pot procedure to afford the resultant amino acid, which was immediately activated by diethyl cyanophosphonate (DEPC) (Yamada et al., 1973) in the presence of collidine to afford cyclopeptide **2a** in 56% yield over two steps. Simultaneous removal of the *tert*-butyl ester

and Boc-protecting group was achieved by treatment of **2a** with trifluoroacetic acid in dichloromethane at room temperature. The guanidino group of the resultant cyclopeptide was monoacylated with *N*-succinimidyl *N*-methylcarbamate (**31**) in the presence of DBU to afford banyasin A **1a** in 66% yield. (Dixon et al., 2005) Having one diastereomer (**1a**), and a practical route to banyasin A in hand, we set out to pursue total syntheses of the other three possible diastereomers. This was readily achieved by following the same synthetic procedure as for **1a**, by employing azido acids **22b**, **22c**, and **22d** as key building blocks. These syntheses proceeded smoothly under the previous conditions to give rise to three diastereomers of banyasin A, **1b**, **1c**, and **1d** in 28, 27, and 30% overall yield from tripeptide **27** (Figure 7).

Conclusions

We have developed a convergent route for the synthesis of the proposed structure of banyasin A. The optical rotation measured for synthetic banyasin A **1a–d** ($[\alpha]_D^{20} = -45.6$ ($c = 0.70$, MeOH); $[\alpha]_D^{20} = -59.4$ ($c = 0.70$, MeOH); $[\alpha]_D^{20} = -37.3$ ($c = 0.70$, MeOH); and $[\alpha]_D^{20} = -53.1$ ($c = 0.70$, MeOH)); were identical or nearly identical to that reported for the natural product ($[\alpha]_D^{20} = -45.3$ ($c = 0.7$, MeOH)). To our disappointment, both the ^1H and ^{13}C spectroscopic properties of each diastereomer **1a**, **1b**, **1c**, and **1d** were different from those of banyasin A (Figure 8 and Supplementary Material). It would appear that the error in the original assignment of the configuration of banyasin A lies somewhere in the remaining α -aminoacids. The extension of this chemistry toward the synthesis of additional diastereomers aiming to resolve the true structure of natural banyasin A and synthesis of novel analogs of banyasin for biological evaluation are underway in our laboratory.

Acknowledgments

We acknowledge financial support from the National Natural Science Foundation of China (21272011, 21133002) and Shenzhen Science and Technology Development Fund (JCYJ20130329175740481); Hong Kong Research Grants Council (Projects: PolyU 5037/11P, 5020/12P; 5030/13P, 153035/14P); Fong Shu Fook Tong Foundation and Joyce M. Kuok Foundation. Part of this work was supported by grants from National Leading Research Lab (NLRL) program (2011-0028885) funded by the Ministry of Science, ICT and Future Planning (MSIP) and the National Research Foundation of Korea (NRF) (to SC). This work was also inspired by the international and interdisciplinary environments of the JSPS Asian CORE Program, “Asian Chemical Biology Initiative.”

Supplementary Material

The Supplementary Material for this article can be found online at: <http://www.frontiersin.org/journal/10.3389/fchem.2015.00019/abstract>

References

- Andersen, O. A., Nathubhai, A., Dixon, M. J., Eggleston, I. M., and van Aalten, D. M. (2008). Structure-based dissection of the natural product cyclopentapeptide chitinase inhibitor argifin. *Chem Biol.* 15, 295–301. doi: 10.1016/j.chembiol.2008.02.015
- Arai, N., Shiomi, K., Yamaguchi, Y., Masuma, R., Iwai, Y., Turberg, A., et al. (2000). Argadin, a new chitinase inhibitor, produced by *clonostachys* sp. fo-7314. *Chem. Pharm. Bull. (Tokyo)* 48, 1442–1446. doi: 10.1248/cpb.48.1442
- Bal, B. S., Childers, W. E., and Pinnick, H. W. (1981). Oxidation of α,β -unsaturated aldehydes. *Tetrahedron* 37, 2091–2096.
- Blakemore, P. R., Cole, W. J., Kocienski, P. J., and Morley, A. (1998). A stereoselective synthesis of trans-1,2-disubstituted alkenes based on the condensation of aldehydes with metallated 1-phenyl-1H-tetrazol-5-yl sulfones. *Synlett* 1998, 26–28. doi: 10.1055/s-1998-1570
- Brown, H. C., and Bhat, K. S. (1986). Enantiomeric Z- and E-crotyldiisopinocampheylboranes. Synthesis in high optical purity of all four possible stereoisomers of β -methylhomallyl alcohols. *J. Am. Chem. Soc.* 108, 293–294. doi: 10.1021/ja00262a017
- Carpino, L. A. (1993). 1-Hydroxy-7-azabenzotriazole. An efficient peptide coupling additive. *J. Am. Chem. Soc.* 115, 4397–4398. doi: 10.1021/ja00063a082
- Dai, L., Chen, B., Lei, H., Wang, Z., Liu, Y., Xu, Z., et al. (2012). Total synthesis and stereochemical revision of lagunamide A. *Chem. Commun.* 48, 8697–8699. doi: 10.1039/c2cc34187e
- Dixon, M. J., Andersen, O. A., van Aalten, D. M. F., and Eggleston, I. M. (2005). An efficient synthesis of argifin: a natural product chitinase inhibitor with chemotherapeutic potential. *Bioorg. Med. Chem. Lett.* 15, 4717–4721. doi: 10.1016/j.bmcl.2005.07.068
- Dixon, M. J., Nathubhai, A., Andersen, O. A., van Aalten, D. M. F., and Eggleston, I. M. (2009). Solid-phase synthesis of cyclic peptide chitinase inhibitors: SAR of the argifin scaffold. *Org. Biomol. Chem.* 7, 259–268. doi: 10.1039/b815077j
- Feichtinger, K., Zapf, C., Sings, H. L., and Goodman, M. (1998). Diprotected triflylguanidines: a new class of guanidinylation reagents. *J. Org. Chem.* 63, 3804–3805. doi: 10.1021/jo980425s
- Gao, X., Liu, Y., Kwong, S., Xu, Z., and Ye, T. (2010). Total synthesis and stereochemical reassignment of bisbromoamide. *Org. Lett.* 12, 3018–3021. doi: 10.1021/ol101021v
- Jokela, J., Herfindal, L., Wahlsten, M., Permi, P., Selheim, F., Vasconcelos, V., et al. (2010). A novel cyanobacterial nostocyclopeptide is a potent anti-toxin against microcystins. *ChemBioChem* 11, 1594–1599. doi: 10.1002/cbic.201000179
- Kang, H.-S., Santarsiero, B. D., Kim, H., Krunic, A., Shen, Q., Swanson, S. M., et al. (2012). Merocyclophanes A and B, antiproliferative cyclophanes from the cultured terrestrial Cyanobacterium *Nostoc* sp. *Phytochemistry* 79, 109–115. doi: 10.1016/j.phytochem.2012.03.005
- Lal, B., Pramanik, B. N., Manhas, M. S., and Bose, A. K. (1977). Diphenylphosphoryl azide a novel reagent for the stereospecific synthesis of azides from alcohols. *Tetrahedron Lett.* 18, 1977–1980. doi: 10.1016/S0040-4039(01)83657-1
- Lei, H., Yan, J., Yu, J., Liu, Y., Wang, Z., Xu, Z., et al. (2014). Total synthesis and stereochemical reassignment of mandelalide A. *Angew. Chem. Int. Ed.* 53, 6533–6537. doi: 10.1002/anie.201403542
- Liu, J., Ma, X., Liu, Y., Wang, Z., Kwong, S., Ren, Q., et al. (2012). Total synthesis and stereochemical revision of burkholdac A. *Synlett* 19, 783–787. doi: 10.1055/s-0031-1290339
- Niedermeyer, T. H. J. (2014). Biologically active natural substances isolated from cyanobacteria of the genus *Nostoc*. *BIOspektrum* 20, 151–153. doi: 10.1007/s12268-014-0420-7
- Omura, S., Arai, N., Yamaguchi, Y., Masuma, R., Iwai, Y., Namikoshi, M., et al. (2000). Argifin, a new chitinase inhibitor, produced by *gliocladium* sp. FTD-0668. i. taxonomy, fermentation, and biological activities. *J. Antibiot. (Tokyo)* 53, 603–608. doi: 10.7164/antibiotics.53.603
- Ploutno, A., and Carmeli, S. (2000). Nostocycline A, a Novel antimicrobial cyclophane from the cyanobacterium *Nostoc* sp. *J. Nat. Prod.* 63, 1524–1526. doi: 10.1021/np0002334
- Ploutno, A., and Carmeli, S. (2002). Modified peptides from a water bloom of the cyanobacterium *Nostoc* sp. *Tetrahedron* 58, 9949–9957. doi: 10.1016/S0040-4020(02)01326-1
- Ploutno, A., and Carmeli, S. (2005). Banyasin A and banyasides A and B, three novel modified peptides from a water bloom of the cyanobacterium *Nostoc* sp. *Tetrahedron* 61, 575–583. doi: 10.1016/j.tet.2004.11.016
- Rao, F. V., Houston, D. R., Boot, R. G., Aerts, J. M. F. G., Hodkinson, M., Adams, D. J., et al. (2005). Specificity and affinity of natural product cyclopentapeptide inhibitors against *A. fumigatus*, human, and bacterial chitinases. *Chem. Biol.* 12, 65–76. doi: 10.1016/j.chembiol.2004.10.013
- Rawat, D., and Bhargava, S. (2011). Bioactive compounds from *Nostoc* species. *Curr. Res. Pharm. Sci.* 2, 48–54.
- Singh, R. K., Tiwari, S. P., Rai, A. K., and Mohapatra, T. M. (2011). Cyanobacteria: an emerging source for drug discovery. *J. Antibiot.* 64, 401–412. doi: 10.1038/ja.2011.21
- Trimurtulu, G., Ohtani, I., Patterson, G. M. L., Moore, R. E., Corbett, T. H., Valeriote, F. A., et al. (1994). Total structures of cryptophycins, potent antitumor depsipeptides from the blue-green alga *Nostoc* sp. Strain GSV 224. *J. Am. Chem. Soc.* 116, 4729–4737. doi: 10.1021/ja00090a020
- Wang, M., Feng, X., Cai, L., Xu, Z., and Ye, T. (2012). Total synthesis and absolute configuration of nocardioazine B. *Chem. Commun.* 48, 4344–4346. doi: 10.1039/c2cc31025b
- Xu, Z., Peng, Y., and Ye, T. (2003). The total synthesis and stereochemical revision of yanucamide A. *Org. Lett.* 5, 2821–2824. doi: 10.1021/ol034803d
- Yamada, S., Kasai, Y., and Shioiri, T. (1973). Diethylphosphoryl cyanide. A new reagent for the synthesis of amides. *Tetrahedron Lett.* 14, 1595–1598. doi: 10.1016/S0040-4039(01)96005-8

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2015 Gao, Ren, Choi, Xu and Ye. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.